Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06YYD
|
|||
| Former ID |
DAP001443
|
|||
| Drug Name |
Dexlansoprazole
|
|||
| Synonyms |
dexlansoprazole; (R)-Lansoprazole; 138530-94-6; Kapidex; dexilant; R-(+)-LANSOPRAZOLE; Dexilant Solutab; TAK 390; UNII-UYE4T5I70X; TAK-390; (r)-(+)-lansoprazole; T 168390; UYE4T5I70X; AK170558; TAK-390MR; T-168390; 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; 2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methylsulfinyl]-1H-benzimidazole; (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; Dexlansoprazole (INN/USAN); Kapidex; KS-1075; Lansoprazole
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Erosive esophagitis [ICD-11: DA25.0] | Approved | [1] | |
| Non-erosive gastro-esophageal reflux disease [ICD-11: DA22.0] | Approved | [1] | ||
| Peptic ulcer [ICD-11: DA61] | Approved | [2], [3] | ||
| NSAID-associated gastric ulcer [ICD-11: DA60; ICD-9: 531] | Phase 3 | [2], [3] | ||
| Company |
Takeda
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H14F3N3O2S
|
|||
| Canonical SMILES |
CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F
|
|||
| InChI |
1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
|
|||
| InChIKey |
MJIHNNLFOKEZEW-RUZDIDTESA-N
|
|||
| CAS Number |
CAS 138530-94-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14901842, 15375021, 23998121, 25819922, 44715913, 80665304, 89736101, 96025586, 104179070, 104234371, 126682042, 128604168, 135156589, 137931058, 140767605, 162189572, 164178109, 164761527, 170503333, 175265917, 175269426, 175611039, 178102134, 184527042, 185965235, 210274918, 210280553, 223658647, 223798807, 226429139, 241033947, 251879797, 252151427, 252431524, 252811271
|
|||
| ChEBI ID |
CHEBI:135931
|
|||
| ADReCS Drug ID | BADD_D00628 ; BADD_D01245 | |||
| SuperDrug ATC ID |
A02BC06
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Blautia obeum
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Blautia obeum was decreased by Lansoprazole (adjusted p-values: 5.04E-06). | |||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Lansoprazole (adjusted p-values: 8.66E-05). | |||
|
Studied Microbe: Dorea formicigenerans
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Dorea formicigenerans was decreased by Lansoprazole (adjusted p-values: 2.31E-05). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Lansoprazole (adjusted p-values: 7.30E-04). | |||
|
Studied Microbe: Roseburia intestinalis
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Roseburia intestinalis was decreased by Lansoprazole (adjusted p-values: 4.29E-04). | |||
|
Studied Microbe: Ruminococcus bromii
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus bromii was decreased by Lansoprazole (adjusted p-values: 1.53E-04). | |||
|
Studied Microbe: Ruminococcus torques
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Ruminococcus torques was decreased by Lansoprazole (adjusted p-values: 2.12E-05). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Gastric H(+)/K(+) ATPase (Proton pump) | Target Info | Modulator | [5] |
| Gastric H(+)/K(+) ATPase alpha (ATP4A) | Target Info | Inhibitor | [6] | |
| KEGG Pathway | Oxidative phosphorylation | |||
| Collecting duct acid secretion | ||||
| Gastric acid secretion | ||||
| Pathwhiz Pathway | Gastric Acid Production | |||
| Reactome | Ion transport by P-type ATPases | |||
| WikiPathways | Iron uptake and transport | |||
| Secretion of Hydrochloric Acid in Parietal Cells | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022287. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7208). | |||
| REF 3 | An overview of proton pump inhibitors. Gastroenterol Nurs. 2003 Sep-Oct;26(5):182-90. | |||
| REF 4 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 5 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||
| REF 6 | Clinical pipeline report, company report or official report of Takeda (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.